IP Library Granted Patent US 7,553,866
Granted Patent B2
US 7,553,866 · App. 11/830,737 · Granted Jun 30, 2009

Thiolactones

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,553,866
App. No.
11/830,737
Granted
Jun 30, 2009
Kind
B2
Abstract

This invention provides new compounds, pharmaceutical compositions and diagnostic kits comprising such compounds, and methods of using such compounds for inhibiting NAALADase enzyme activity, detecting diseases where NAALADase levels are altered, inhibiting angiogenesis, effecting a TGF-β activity or a neuronal activity, and treating a glutamate abnormality, a compulsive disorder, neuropathy, pain, a prostate disease, cancer, Huntington's disease, diabetes, a retinal disorder or glaucoma.

Claims (27)

1. A compound of formula I

or a pharmaceutically acceptable salt, an optical isomer or a mixture of optical isomers of the compound, wherein:

X is C 1 -C 4 alkylene or Ar;

Ar is phenylene which is unsubstituted or substituted with one or more substituent(s) independently selected from carboxy, halo, nitro, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, phenyl, phenoxy and benzyloxy;

L is a bond, —CR 1 R 2 —, —O—, —S—, or —NH;

Y is —CR 3 R 4 —;

Z is —(CR 5 R 6 ) 2 —; and

R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are independently hydrogen, C 1 -C 4 alkyl or C 2 -C 4 alkenyl, wherein the alkyl or alkenyl is unsubstituted or substituted with one or more substituent(s);

provided that when L is a bond then X is methylene, propylene, butylene, or Ar.

2. The compound of claim 1 , wherein L is —CR 1 R 2 —.

3. The compound of claim 1 , wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are each hydrogen.

4. The compound of claim 1 , wherein X is Ar.

5. The compound of claim 1 , wherein:

L is —CR 1 R 2 —;

R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are each hydrogen; and

X is Ar.

6. The compound of claim 5 , wherein Ar is phenylene substituted with one or more substituent(s) independently selected from carboxy, halo, nitro, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, phenyl, phenoxy and benzyloxy.

7. The compound of claim 5 , wherein Ar is phenylene substituted with carboxy.

8. The compound of claim 5 , wherein Ar is phenylene substituted with halo.

9. The compound of claim 5 , wherein Ar is phenylene substituted with nitro.

10. The compound of claim 5 , wherein Ar is phenylene substituted with C 1 -C 4 alkyl.

11. The compound of claim 5 , wherein Ar is phenylene substituted with C 1 -C 4 alkoxy.

12. A method for treating peripheral neuropathy, comprising administering to a mammal in need thereof an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt, an optical isomer or a mixture of optical isomers of the compound.

13. The method of claim 12 , wherein the peripheral neuropathy is HIV-, chemical- or vitamin-induced.

14. A pharmaceutical composition comprising:

(i) an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt, an optical isomer or a mixture of optical isomers of the compound; and

(ii) a pharmaceutically acceptable carrier.